IP Library Granted Patent US 9,663,758
Granted Patent B2
US 9,663,758 · App. 14/193,818 · Granted May 30, 2017

Global gene regulators (GGR) as vaccine candidates against paratuberculosis

Inventor: Adel M. Talaat (Madison, WI)
Assignee: Wisconsin Alumni Research Foundation
C12N1/20A61K39/04C07K14/195C07K14/35C12N1/36C12Q1/689G01N33/5695A61K2039/522C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,663,758
App. No.
14/193,818
Granted
May 30, 2017
Kind
B2
Abstract

Described herein is a mycobacterium mutant, comprising at least one mutation in at least one gene sequence encoding global gene regulators (GGRs) selected from the group consisting of sigH, sigL, sigE, ECF-1, and mixtures thereof, wherein the GGR gene is at least partially inactivated. Described herein also is a vaccine based on the mutant and a method of differentiating between subjects that have been infected with mycobacterium and subjects that have not been infected with mycobacterium or have been vaccinated with a mycobacterium vaccine.

Claims (19)

1. A mycobacterium mutant, wherein the mycobacterium is selected from the group consisting of Mycobacterium avium subspecies paratuberculosis (M. ap) and Mycobacterium bovis ( M. bovis ), comprising at least one mutation in at least one gene sequence selected from the group consisting of sigL and ECF-1, which encode a global gene regulator (GGR), wherein the GGR gene is at least partially inactivated.

2. The mutant of claim 1 , wherein the mycobacterium is M. ap.

3. The mutant of claim 1 , wherein the mycobacterium is M. bovis.

4. A mycobacterium mutant, wherein the mycobacterium is Mycobacterium avium subspecies paratuberculosis (M. ap), comprising at least one mutation in sigL (SEQ ID NO:2), which encodes a global gene regulator (GGR), or a sequence substantially identical to SEQ ID NO:2, wherein the GGR is at least partially inactivated.

5. The mutant of claim 1 , wherein the GGR is M. ap ECF-1 (SEQ ID NO:4) or a sequence substantially identical to SEQ ID NO:4.

6. The mutant of claim 1 , wherein the inactivation is achieved by at least partial deletion of a gene sequence encoding a GGR.

7. The mutant of claim 6 , wherein the inactivation is achieved by a complete deletion of a gene sequence encoding a GGR.

8. The mutant of claim 1 , wherein the inactivation is achieved by at least partial transposon insertion of a gene sequence encoding a GGR.

9. The mutant of claim 8 , wherein the inactivation is achieved by a complete transposon insertion of a gene sequence encoding a GGR.

10. The mutant of claim 1 , wherein the inactivation is achieved using a partial anti-sense construct of a gene sequence encoding a GGR.

11. The mutant of claim 10 , wherein the inactivation is achieved using a complete anti-sense construct of a gene sequence encoding a GGR.

12. An isolated mycobacterial organism comprising a mutation according to claim 1 , wherein the mycobacterium is selected from the group consisting of Mycobacterium avium subspecies paratuberculosis (M. ap) and Mycobacterium bovis ( M. bovis ).

13. A mycobacterium vaccine comprising a mycobacterium mutant according to claim 1 .

14. A mycobacterium vaccine comprising an isolated mycobacterial organism comprising a mycobacterium mutant, wherein the mycobacterium is selected from the group consisting of Mycobacterium avium subspecies paratuberculosis (M. ap) and Mycobacterium bovis ( M. bovis ), comprising at least one mutation in sigL, which encodes a global gene regulator (GGR), wherein the GGR gene is at least partially inactivated.

15. The vaccine of claim 14 , wherein the vaccine is physically inactivated.

16. The vaccine of claim 15 , wherein the vaccine is heat inactivated.

17. The vaccine of claim 14 , wherein the vaccine is chemically inactivated.

18. The vaccine of claim 17 , wherein the vaccine is formaldehyde inactivated.

19. The vaccine of claim 14 , wherein the vaccine is a live attenuated vaccine.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 3, 2014
From: TALAAT, ADEL; GHOSH, PALLAB
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 032591/0951 →
Continuity (2)
Provisional Application 61777907 · Mar 12, 2013
Related Publication 20140271719A1 · Sep 18, 2014